This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameTalazoparib
Accession NumberDB11760
TypeSmall Molecule
GroupsInvestigational
Description

Talazoparib is under investigation for the treatment of Childhood Solid Tumors.

Structure
Thumb
SynonymsNot Available
External IDs BMN 673 / BMN-673 / LT-673
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII9QHX048FRV
CAS number1207456-01-6
WeightAverage: 380.359
Monoisotopic: 380.119715421
Chemical FormulaC19H14F2N6O
InChI KeyHWGQMRYQVZSGDQ-HZPDHXFCSA-N
InChI
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
IUPAC Name
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(1-methyl-1H-1,2,4-triazol-5-yl)-2,3,10-triazatricyclo[7.3.1.0^{5,13}]trideca-1,5,7,9(13)-tetraen-4-one
SMILES
CN1N=CN=C1[[email protected]@H]1[[email protected]](NC2=C3C1=NNC(=O)C3=CC(F)=C2)C1=CC=C(F)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Bmn 673.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Bmn 673.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bmn 673.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Bmn 673.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Bmn 673.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Bmn 673.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Bmn 673.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bmn 673.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Bmn 673.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Bmn 673.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Bmn 673.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Bmn 673.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
1Active Not RecruitingTreatmentBRCA-mutated Solid Tumor / Triple Negative Metastatic Breast Cancer1
1Active Not RecruitingTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor1
1CompletedOtherHuman Volunteers1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced or Recurrent Solid Tumors / Ewing's Sarcoma (ES) / Malignant Neoplasm of Pancreas / Neoplasms, Breast / Ovarian Cancer, Epithelial / Prostate Cancer / Small Cell Lung Carcinoma1
1Not Yet RecruitingTreatmentEstrogen Receptor Negative / Head and Neck Squamous Cell Carcinoma (HNSCC) / HER2/Neu Negative / Hormone-Resistant Prostate Cancer / Pancreatic Adenocarcinoma Metastatic / Progesterone Receptor Negative / Solid Neoplasms / Stage III Mesothelioma / Stage IIIA Gastric Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Small Cell Lung Carcinoma / Stage IIIB Gastric Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Small Cell Lung Carcinoma / Stage IIIC Gastric Cancer / Stage IIIC Ovarian Cancer / Stage IV Mesothelioma / Stage IV Non-Small Cell Lung Cancer / Stage IV Ovarian Cancer / Stage IV Small Cell Lung Carcinoma / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentAdvanced Malignant Solid Neoplasm / BRCA Rearrangement / BRCA1 Gene Mutation / Brca2 Gene Mutation / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Metastatic Malignant Solid Neoplasm / Solid Neoplasms / Unresectable Solid Neoplasm1
1RecruitingTreatmentAdvanced Solid Tumors3
1RecruitingTreatmentChildhood Solid Tumors1
1RecruitingTreatmentTumors, Solid1
1WithdrawnTreatmentAdult Solid Neoplasm / Estrogen Receptor Negative / Fallopian Tube Serous Neoplasm / HER2/Neu Negative / Ovarian Serous Adenocarcinoma / Ovarian Serous Tumor / Primary Peritoneal Serous Adenocarcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Triple-Negative Breast Carcinoma1
1WithdrawnTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer / Tumors, Solid1
1, 2CompletedTreatmentAdvanced Breast Cancer / Advanced Ovarian Cancer / Advanced Solid Tumors / Primary Peritoneal Cancer1
1, 2Not Yet RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Central Nervous System Neoplasm / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Malignant Solid Neoplasm / Refractory Central Nervous System Neoplasm1
2Active Not RecruitingTreatmentAdvanced Cancers1
2Active Not RecruitingTreatmentBRCA 1 Gene Mutation / BRCA 2 Gene Mutation / Neoplasms, Breast1
2CompletedTreatmentCancer, Ovarian1
2RecruitingTreatmentAdvanced Breast Cancer / HER2/Neu Negative / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancers1
2RecruitingTreatmentProstate Cancer1
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentEndometrial Cancers1
3Active Not RecruitingTreatmentBRCA 1 Gene Mutation / BRCA 2 Gene Mutation / Neoplasms, Breast1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.101 mg/mLALOGPS
logP2.93ALOGPS
logP2.11ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.48ChemAxon
pKa (Strongest Basic)1.66ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.2 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.27 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassPhenylquinolines
Direct ParentPhenylquinolines
Alternative ParentsPhthalazinones / Secondary alkylarylamines / Pyridazinones / Fluorobenzenes / Aralkylamines / Aryl fluorides / Triazoles / Heteroaromatic compounds / Lactams / Azacyclic compounds
SubstituentsPhenylquinoline / Phthalazinone / Phthalazine / Fluorobenzene / Halobenzene / Pyridazinone / Secondary aliphatic/aromatic amine / Aralkylamine / Aryl halide / Aryl fluoride
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 14:45 / Updated on September 01, 2017 12:12